Clinical Trials Browser

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT03070548 2018-12-17

A Study of Talazoparib in Patients With Advanced Solid Tumors

Phase 1 Completed

6 enrolled 34 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01399840 2017-09-15

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Phase 1 Completed

33 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell

NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Withdrawn

BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02537561 2016-02-11

Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Talazoparib

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

PARPAML

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

PARLuNET

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

REPAIR

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

A Study of Talazoparib in Patients With Advanced Solid Tumors

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors